Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Belle Health vs Lttl

Belle Health
Graded #48

Higher grade

vs+10.900000000000006
Lttl
Graded #204

Lower grade

The verdict

Belle Health takes it — 77/100 to 66.1/100.

Belle Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Belle Health is a national DTC telehealth platform offering compounded semaglutide and tirzepatide with flat-rate pricing — the same monthly cost at every dose, with no escalation surcharge as you titrate up.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBelle Health +36
92
56
Dose & formulationLttl +24
72
96
Clinical oversightLttl +5
71
76
Labs & monitoringBelle Health +20
72
52
FulfillmentBelle Health +16
85
69
Contract termsBelle Health +35
55
20
Belle Health · left barLttl · right bar

The numbers

MetricBelle HealthLttl
WeighScore77/10066.1/100
GradeC+C
Scorecard rank#48#204
Semaglutide$119/mo$199/mo (all doses, compounded)
Tirzepatide$199/mo (all doses, 3-month plan, compounded)$279/mo (all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Belle Health

Graded #48 · C+

Strengths

  • Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
  • Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
  • Free weekly registered-dietitian sessions included
  • Operating since 2017
  • LegitScript Certified

Where it loses points

  • $199 tirzepatide price requires a 3-month bundle commitment
  • Compounded medications are not FDA-approved
  • Multi-pharmacy model — formulations may differ across orders
  • FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Lttl

Graded #204 · C

Strengths

  • Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
  • Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
  • States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
  • Oral ODT semaglutide offered for members who want to avoid injections

Where it loses points

  • Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
  • The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
  • No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
  • Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
  • Medications cannot be returned or refunded once they ship from the pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard